Clarifications in JAMA Clinical Guidelines Synopsis
In the JAMA Clinical Guidelines Synopsis titled “Antiviral Therapies for Adults With Mild to Moderate COVID-19 Infection,” published online June 30, 2026, several points were rewritten for clarification. In the third paragraph of the Evidence Base section, the second sentence was revised to “Coadministration of nirmatrelvir-ritonavir is contraindicated with certain medications due to risk of…
The JAMA Clinical Guidelines Synopsis, "Antiviral Therapies for Adults With Mild to Moderate COVID-19 Infection," published online on June 30, 2026, had several points rewritten for clarity. In the Evidence Base section, the second sentence of the third paragraph was altered to specify the contraindications of coadministering nirmatrelvir-ritonavir with certain medications such as amiodarone, statins, phosphodiesterase 5 inhibitors, α-blockers, and benzodiazepines, as well as strong CYP3A inducers like rifampin, carbamazepine, and St John’s wort.
The last sentence of the fifth paragraph in the Evidence Base section was also revised to advise patients who may become pregnant to use contraception during molnupiravir treatment and for four days after the last dose if their partner did not also use molnupiravir. Individuals who have a male partner who used molnupiravir are advised to use effective contraception for three months post-treatment.
Additionally, breastfeeding patients are encouraged to consider interrupting breastfeeding and pump and discard breast milk during molnupiravir treatment and for four days following the last dose. The second paragraph of the Discussion section included an extra sentence about molnupiravir, stating that it is currently only available in the US through Emergency Use Authorization, with the authorization set to end on June 29, 2027. This article was subsequently corrected online.
Written by urgent.news from JAMA's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
